NO20033117L - Farmasöytiske blandinger som inhiberer vaskul¶r proliferasjon og metoder for anvendelse derav - Google Patents

Farmasöytiske blandinger som inhiberer vaskul¶r proliferasjon og metoder for anvendelse derav

Info

Publication number
NO20033117L
NO20033117L NO20033117A NO20033117A NO20033117L NO 20033117 L NO20033117 L NO 20033117L NO 20033117 A NO20033117 A NO 20033117A NO 20033117 A NO20033117 A NO 20033117A NO 20033117 L NO20033117 L NO 20033117L
Authority
NO
Norway
Prior art keywords
methods
pharmaceutical compositions
vascular proliferation
inhibit vascular
inhibit
Prior art date
Application number
NO20033117A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033117D0 (no
Inventor
Michael Dewitt Culler
Romano Danesi
Guido Bocci
Mario Deltacca
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20033117D0 publication Critical patent/NO20033117D0/no
Publication of NO20033117L publication Critical patent/NO20033117L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
NO20033117A 2001-01-12 2003-07-08 Farmasöytiske blandinger som inhiberer vaskul¶r proliferasjon og metoder for anvendelse derav NO20033117L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26143901P 2001-01-12 2001-01-12
US27529401P 2001-03-13 2001-03-13
PCT/US2002/001125 WO2002064160A2 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof

Publications (2)

Publication Number Publication Date
NO20033117D0 NO20033117D0 (no) 2003-07-08
NO20033117L true NO20033117L (no) 2003-09-04

Family

ID=26948607

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033117A NO20033117L (no) 2001-01-12 2003-07-08 Farmasöytiske blandinger som inhiberer vaskul¶r proliferasjon og metoder for anvendelse derav

Country Status (15)

Country Link
US (1) US7084117B2 (ja)
EP (1) EP1409007A2 (ja)
JP (1) JP4099065B2 (ja)
KR (1) KR20030068585A (ja)
CN (1) CN1531441A (ja)
AU (1) AU2002243552C1 (ja)
CA (1) CA2433785C (ja)
CZ (1) CZ20031695A3 (ja)
HU (1) HUP0302732A2 (ja)
IL (1) IL156506A0 (ja)
NO (1) NO20033117L (ja)
NZ (1) NZ526676A (ja)
PL (1) PL361879A1 (ja)
RU (1) RU2288739C2 (ja)
WO (1) WO2002064160A2 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109166B1 (en) * 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
DK1406895T3 (da) 2001-06-13 2008-12-01 Magnachem Int Lab Inc Lactonformuleringer og fremgangsmåde til anvendelse deraf
JP2005518335A (ja) * 2001-06-25 2005-06-23 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 下垂体腺腫の増殖を阻害する医薬組成物およびそれを使用する方法
US8188145B2 (en) 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
US7098187B2 (en) * 2002-09-13 2006-08-29 Attenuon, Llc Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
KR20050059319A (ko) * 2002-10-31 2005-06-17 센주 세이야꾸 가부시키가이샤 각막 장해 치료제
MXPA05004794A (es) 2002-11-05 2005-08-19 Magnachem Int Lab Inc Formulaciones de lactonas y metodos de uso.
EP1692099A1 (en) * 2003-12-12 2006-08-23 Oy Juvantia Pharma Ltd Somatostatine receptor subtype 1 (sstr1) active compounds and their use in therapy
CN1317031C (zh) * 2005-09-14 2007-05-23 上海第二医科大学附属新华医院 增强实体肿瘤细胞化疗敏感性的高效混合制剂
ES2658101T3 (es) 2008-02-21 2018-03-08 Hexacath Dispositivo médico implantable con una capa de protección/retención de un agente activo o medicamento, en concreto, hidrosoluble
US8969450B2 (en) 2009-12-01 2015-03-03 Bridgestone Corporation Modified rubber compositions and methods of preparation
FR3052075B1 (fr) 2016-06-01 2022-01-07 Hexacath Dispositif formant catheter d'infusion pour traiter au moins une obstruction partielle ou totale dans un conduit, tel que conduit corporel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
TW334434B (en) * 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
JP2002500623A (ja) * 1996-11-07 2002-01-08 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニヴァーシティー スプルーティタンパク質およびコーディング配列
US6124256A (en) * 1998-03-27 2000-09-26 Haeyry; Pekka Method for the prevention of a patient's fibroproliferative vasculopathy
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
WO2000010552A2 (en) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
CA2246791A1 (en) * 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
US6903074B1 (en) * 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US20020103526A1 (en) * 2000-12-15 2002-08-01 Tom Steinke Protective coating for stent

Also Published As

Publication number Publication date
RU2288739C2 (ru) 2006-12-10
US20040082517A1 (en) 2004-04-29
RU2003124748A (ru) 2005-01-10
CN1531441A (zh) 2004-09-22
KR20030068585A (ko) 2003-08-21
WO2002064160A8 (en) 2003-01-30
PL361879A1 (en) 2004-10-04
CZ20031695A3 (en) 2004-03-17
AU2002243552C1 (en) 2006-08-31
WO2002064160A3 (en) 2004-02-19
IL156506A0 (en) 2004-01-04
US7084117B2 (en) 2006-08-01
HUP0302732A2 (hu) 2003-12-29
JP4099065B2 (ja) 2008-06-11
EP1409007A2 (en) 2004-04-21
CA2433785A1 (en) 2002-08-22
AU2002243552B2 (en) 2005-03-10
WO2002064160A2 (en) 2002-08-22
NZ526676A (en) 2005-03-24
NO20033117D0 (no) 2003-07-08
JP2004527483A (ja) 2004-09-09
CA2433785C (en) 2009-08-04

Similar Documents

Publication Publication Date Title
NO20033565D0 (no) Acylerte indanylaminer og deres anvendelse som farmasöytiske midler
DK1564210T5 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
DK1401806T3 (da) Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler
CY2015003I1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
NO20050830L (no) Acylerte heteroarylkondenserte sykloalkenylaminer og deres anvendelse som farmasoytiske midler
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1484970T3 (da) Benzamider og sammensætninger omfattende benzamider til anvendelse som fungicider
DK1242095T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20024925L (no) Flerbruks-kirurgisk sementdispenserapparat og utrustning for samme
DK1448195T3 (da) N-adamantylmethylderivater og mellemprodukter som farmaceutiske præparater og fremgangsmåde til fremstilling deraf
DK1562556T3 (da) Farmaceutiske sammensætninger og doseringsformer af thalidomid
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
HUP0400202A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect, their use and pharmaceutical compositions containing them
DK1354873T3 (da) Perindoaprilsalt og farmaceutiske sammensætninger indeholdende dette
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1411921T4 (da) Farmaceutiske sammensætninger indeholdende terbinafin og anvendelse deraf
NO20033117L (no) Farmasöytiske blandinger som inhiberer vaskul¶r proliferasjon og metoder for anvendelse derav
IS2841B (is) Samstæða hluta og lyfjasamsetningar
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DK1849468T3 (da) Farmaceutisk sammensætning omfattende roflumilast og levocetirizin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application